Prostate Cancer | Specialty

Role of PRRT in the Management of NETs

March 1st 2018

Deciding on SSA Treatment in NETs

March 1st 2018

Overview of Somatostatin Analogs for NETs

March 1st 2018

Symptom Control in Functional NETs

March 1st 2018

Risk Stratification and Management of NETs

March 1st 2018

Surgical Considerations for Neuroendocrine Tumors

March 1st 2018

Advances in the Management of NETs

March 1st 2018

Degarelix May Reduce Risk of Cardiovascular Events in Prostate Cancer

February 27th 2018

Susan F. Slovin, MD, PhD, discusses the multinational PRONOUNCE study and how the results may affect the treatment of patients with prostate cancer.

Dr. Gomella on Enzalutamide in Prostate Cancer

February 27th 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses enzalutamide (Xtandi) for patients with nonmetastatic castration-resistant prostate cancer.

Gomella Discusses Apalutamide Approval and Other Progress in Prostate Cancer

February 23rd 2018

Leonard Gomella, MD, shares his insight on the recent FDA approvals and other ongoing progress in the treatment of patients with prostate cancer.

Dr. Slovin Discusses GnRH Antagonists Versus Agonists

February 23rd 2018

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the difference between GnRH antagonists and GnRH agonists.

Dr. Wise Discusses Challenges With Immunotherapy in Prostate Cancer

February 22nd 2018

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses challenges with immunotherapy in prostate cancer.

CTCs Demonstrate Predictive Power in Prostate Cancer

February 21st 2018

Investigators looking for a superior means of testing for response to therapy in metastatic castration-resistant prostate cancer said they found the solution in a study of circulating tumor cells.

Dr. Gomella on the FDA Approval of Apalutamide for Nonmetastatic CRPC

February 20th 2018

Leonard Gomella, MD, professor, chair, Department of Oncology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Maintaining Bone Health During ADT for Prostate Cancer

February 20th 2018

The use of androgen deprivation therapy in prostate cancer is now a well-established treatment regimen but is associated with an increased risk for bone fracture.

Dr. Koontz on Next Steps for Study of LHRH in Prostate Cancer

February 20th 2018

Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses the next steps for the phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

Dr. Gulley on Take Home Message With Olaparib Plus Durvalumab in mCRPC

February 17th 2018

James Gulley, MD, PhD, chief, Genitourinary Malignancies Branch, and director, Medical Oncology Service at the National Cancer Institute, discusses the take-home message with the combination of olaparib (Lynparza) plus durvalumab (Imfinzi) in metastatic castration-resistant prostate cancer.

Dr. Slovin on an Ongoing Study With Degarelix Leuprolide in Prostate Cancer

February 16th 2018

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.

FDA Approves Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

February 15th 2018

The FDA has approved apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Wise on the FDA Approval of Apalutamide in Non-Metastatic CRPC

February 14th 2018

David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).